康寧傑瑞製藥(09966.HK)治療乳腺癌新藥將於美國癌症研究協會呈列
康寧傑瑞製藥-B(09966.HK)公布,關於使用轉譯腫瘤生長抑制模型及群體藥代動力學分析方法預測KN026(一種基於Fc的抗人表皮生長因子受體2的雙特異性單克隆抗體)治療HER2陽性轉移性乳腺癌患者的有效劑量的摘要已獲2020年美國癌症研究協會年會接受以海報形式呈列。
公司希望通過使用轉譯腫瘤生長抑制模型,縮短從早期開發至全面開發的研發週期,這有助加快KN026在主要地區的註冊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.